PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TARGET CANCER INCLUDING BRCA-SPECIFIC siRNA AS ACTIVE INGREDIENT
AssigneesKorea Institute of Science and Technology, Dana-Farber Cancer Institute, Inc.
InventorsJu Hee RYU, Ick Chan KWON, Youngji KO, Thomas M. ROBERTS, Jean J. ZHAO, Liya DING
Life of this patent
Estimating the term…
Abstract
Provided is BRCA-specific siRNA for enhancing the sensitivity of cancer cells to PARP inhibitors. According to the present disclosure, the siRNA can induce cancer cell death together with the PARP inhibitors in patients with wild-type BRCA genes with a low therapeutic effect of the PARP inhibitors, and the fusion protein-siRNA complex for siRNA delivery is up-taken into cells via CD47, and thus more specifically delivered to cancer cells while up-taken with high efficiency, thereby maximizing a desired cell death effect.
Claims12
A pharmaceutical composition for preventing or treating cancer comprising breast cancer susceptibility gene (BRCA) 1-specific small interfering RNA (siRNA) and/or BRCA2-specific siRNA as an active ingredient,
- wherein the composition is administered in combination with a poly ADP-ribose polymerase (PPAR) inhibitor.
A composition for enhancing sensitivity of cancer cells to a PPAR inhibitor, comprising BRCA1-specific siRNA and/or BRCA2-specific siRNA as an active ingredient.
A fusion protein-siRNA complex in which siRNA is conjugated with a fusion protein in which a SIRPα protein and a linker peptide cleaved by a lysosomal enzyme are covalently linked to each other, wherein the siRNA includes a nucleotide sequence represented by SEQ ID NO:
- 3 or SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.